Company Overview and News

3
Tullow Oil: H1 Results And H2 Expectations

2018-10-12 seekingalpha
As an E&P company, Tullow Oil has faced severe pressure since 2014 oil prices crash and even lost its place in the FTSE 100 Index.
CNE ECAOF XOM CRNZF TLW KOS CRNCY

2
Kosmos Energy to Abandon Pontoenoe-1, Issues Business Update

2018-10-11 zacks
Kosmos Energy Ltd (KOS - Free Report) plans to abandon the well — the Pontoenoe-1 — in Block 42 offshore Suriname, after it failed to discover oil. This turned out to be the second dry well in the region in recent months. High-quality reservoir was discovered offshore Suriname but the main exploration goal proved to be water bearing. Also, the company did not encounter commercial hydrocarbons. Kosmos Energy, the exploration operator of Block 42, holds 33.
HES CVX KOS

2
[Press] Kosmos Energy Announces Results of Pontoenoe-1 Well and Provides Operational and Financial Update

2018-10-11 oilvoice
Kosmos Energy (NYSE: KOS)(LSE: KOS) announced today that it has completed drilling the Pontoenoe-1 exploration well in Block 42 offshore Suriname.
HES CVX KOS

 
KOS / Kosmos Energy Ltd. FORM 8-K (Current Report)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
KOS

1
 
KOS / Kosmos Energy Ltd. FORM 8-K (Current Report)

2018-10-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
KOS

1
KOS / Kosmos Energy Ltd. FORM 8-K (Current Report)

2018-09-26 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
KOS

1
KOS / Kosmos Energy Ltd. / First Reserve GP XIII Ltd - 13G (Passive Investment)

2018-09-24 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
KOS

 
KOS / Kosmos Energy Ltd. / First Reserve GP XIII Ltd - 13G (Passive Investment)

2018-09-24 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
KOS

 
5
Kosmos Energy (KOS) Completes Buyout of Deep Gulf Energy

2018-09-18 zacks
Kosmos Energy Ltd. (KOS - Free Report) completed the earlier announced acquisition of Deep Gulf Energy (“DGE”). The acquisition enabled the company expand the deepwater Atlantic Margin portfolio. DGE collectively comprises Deep Gulf Energy LP, Deep Gulf Energy II, LLC, Deep Gulf Energy III, LLC and related entities. Currently, the company’s assets are concentrated in Africa and South America. The assets in Atlantic Margin are attractive and project an impressive record of increasing production and reserves through infrastructure-led explorations.
HLX TCP MDPEB MDP KOS

 
[Press] Kosmos Energy Completes Acquisition of Deep Gulf Energy

2018-09-17 oilvoice
DALLAS--(BUSINESS WIRE)--Sep. 17, 2018-- Kosmos Energy (NYSE: KOS) (LSE: KOS) announced today that it has completed the previously announced acquisition of Deep Gulf Energy (“DGE”)1, a leading deepwater company operating in the Gulf of Mexico. By acquiring DGE, Kosmos adds to its deepwater Atlantic Margin portfolio an established business with attractive assets and a strong record of growing production and reserves through infrastructure-led exploration.
KOS

 
[Opinion] In South America ExxonMobil’s Success in Guyana is Taking the Guyana-Suriname Basin to be Second Only to Pre-Salt Brazil, Says GlobalData

2018-09-05 oilvoice
Adrian Lara, Senior Oil and Gas Analyst at GlobalData, a leading data and analytics company, offers his view on the impact on the upstream sector:
TLW KOS

 
SEC Ends Investigation On Ensco DS-5 Contract

2018-09-05 seekingalpha
I look at the former Atwood fleet to find out how the acquisition has worked out for Ensco so far.
ATW ESV RIG KOS

 
5 Reasons Why You Should Invest in Kosmos Energy Stock Now

2018-09-04 zacks
Kosmos Energy Ltd. (KOS - Free Report) looks compelling at the moment. Given the company’s strong fundamentals as well as positive estimate revisions, it seems like this is the right time to add the stock to your portfolio.
HLX MDR KOS MCDFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to KOS / Kosmos Energy Ltd. on message board site Silicon Investor.

GeckoSystems, Mobile Robot Solutions for Safety , Security a GeckoSystems, Mobile Robot Solutions for Safety , Security a GeckoSystems, Mobile Robot Solutions for Safety , Security a Oshkosh Truck Corporation Oshkosh Truck Corporation Oshkosh Truck Corporation
Kosan BioSciences -- KOSN Kosan BioSciences -- KOSN Kosan BioSciences -- KOSN Russian Oil Company: Yukos (YUKOY) Russian Oil Company: Yukos (YUKOY) Russian Oil Company: Yukos (YUKOY)
Russian Stocks : Lukoil, Yukos, VIP, ROS, ... Russian Stocks : Lukoil, Yukos, VIP, ROS, ... Russian Stocks : Lukoil, Yukos, VIP, ROS, ... Kos Pharmaceuticals, Inc (KOSP) Kos Pharmaceuticals, Inc (KOSP) Kos Pharmaceuticals, Inc (KOSP)
Kosovo Kosovo Kosovo Kostroma State District Power Station Kostroma State District Power Station Kostroma State District Power Station
IKOS Systems IKOS Systems IKOS Systems NIKOS EXPLORATIONS-NIK.V--In JV with SOP.A in Cal Canal NIKOS EXPLORATIONS-NIK.V--In JV with SOP.A in Cal Canal NIKOS EXPLORATIONS-NIK.V--In JV with SOP.A in Cal Canal
CUSIP: G5315B107